Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00656786 | Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash | PHASE1 | COMPLETED | 18 | — | — | Apr 3, 2008 | Dec 30, 2009 | Nov 13, 2020 | 7 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Subjects will be treated if, after starting treatment with an EGFRi, acute signs and symptoms of rash on the face/neck and/or upper chest emerge, that are suspected of being related to the EGFRi treatment. |
| Group 2 | EXPERIMENTAL | Subjects will receive pre-emergent rash treatment starting 1 day prior to beginning EGFRi therapy |
| Name | Type | Description |
|---|---|---|
| Menadione Topical Lotion | DRUG | Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy. |
Inclusion Criteria: 1. Male or female subjects at least 18 years old; 2. Have been prescribed an approved EGFRI to treat cancer and expect to begin this treatment within 14 days (i.e., any EGFRI that is approved for the treatment of cancer at the time of subject enrollment); 3. For Group 1: Agree t...